TY - JOUR
T1 - Quality of life in the trastuzumab for gastric cancer trial
AU - Satoh, Taroh
AU - Bang, Yung Jue
AU - Gotovkin, Evgeny A.
AU - Hamamoto, Yasuo
AU - Kang, Yoon Koo
AU - Moiseyenko, Vladimir M.
AU - Ohtsu, Atsushi
AU - Van Cutsem, Eric
AU - Al-Sakaff, Nedal
AU - Urspruch, Alexa
AU - Hill, Julie
AU - Weber, Harald A.
AU - Chung, Hyun Cheol
PY - 2014
Y1 - 2014
N2 - Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.
AB - Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.
UR - http://www.scopus.com/inward/record.url?scp=84903631229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903631229&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2014-0058
DO - 10.1634/theoncologist.2014-0058
M3 - Article
C2 - 24951609
AN - SCOPUS:84903631229
VL - 19
SP - 712
EP - 719
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 7
ER -
